Skip to content
cccskills
FreePublished on GitHub

enda-adjust-glucocorticoid-clinical-response

The Endocrine Society guideline recommends against routine hormonal monitoring of glucocorticoid replacement in primary adrenal insufficiency and advises adjusting therapy solely based on clinical response. Use when evaluating glucocorticoid dose adequacy, such as when patients report fatigue, weight loss, hypotension, or signs of Cushingoid over-replacement.

The English summary is being prepared. Showing the original description.

Run score Not tested

See how to install

Files included (1)

  • SKILL.md2.2 KB

SKILL.md (original)

Review the instructions the agent will receive before you install.

Adjust Glucocorticoid Treatment Based Solely on Clinical Response

STEP 1 — Gather Information

Collect clinical symptoms and signs of glucocorticoid over- or under-replacement: weight change, appetite, energy levels, blood pressure, peripheral edema, hyperpigmentation, and patient-reported well-being.

STEP 2 — Rule In / Rule Out

Is there clinical evidence of glucocorticoid excess or deficiency? If yes, proceed to classification; if no, maintain current dose and reassess in 4–6 weeks.

STEP 3 — Classify or Stratify

Classify as over-replacement (Cushingoid signs: weight gain, insomnia, peripheral edema, etc.), under-replacement (fatigue, weight loss, hypotension, hyperpigmentation, etc.), or adequate (stable weight, normal energy, no symptoms).

STEP 4 — Decide

If over-replacement, reduce glucocorticoid dose by 2.5–5 mg hydrocortisone equivalent; if under-replacement, increase dose by 2.5–5 mg; if adequate, continue current regimen.

Clinical Guardrails / Mimics / Pitfalls

Do not rely on ACTH or cortisol levels to guide dosing; avoid over-reliance on hormonal monitoring. Symptoms can be nonspecific—consider concurrent illness, stress, or pregnancy. Avoid abrupt dose changes; taper adjustments. Monitor for signs of adrenal crisis during dose reduction.

Concrete Clinical Example

A 48-year-old man on hydrocortisone 15 mg daily reports progressive fatigue and 3 kg weight loss over 2 months, with postural hypotension; no Cushingoid signs. Clinical assessment suggests under-replacement; dose increased to 20 mg daily, with symptom reassessment scheduled in 4 weeks.

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI: 10.1210/jc.2015-1710

Reviews

No reviews yet. Tell others what you thought.

Comments

No login needed. Share how it worked for you, ask a question, or note where it did not run.

No comments yet. Be the first to write one.

Comments are published right away. Do not include personal information such as email addresses or phone numbers. Up to 2 URLs.

0 / 1,000 characters

This form is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply.

More skills from this repository

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

See all skills by dromlakhani

Report a problem with this skill